Literature DB >> 19004004

Is norepinephrine an etiological factor in some types of cancer?

Paul J Fitzgerald1.   

Abstract

I examine evidence that the signaling molecule norepinephrine (NE) is an etiological factor in some types of cancer. In support of this hypothesis, I cite the following 7 lines of evidence: (i) rodent studies of tumorigenesis in the context of NE manipulation; (ii) human studies of tricyclic antidepressant use and cancer rate; (iii) existence of pheochromocytoma, a cancer of the adrenal glands; (iv) cancer rate in families with individuals who have bipolar disorder; (v) hypertension and cancer risk; (vi) excessive body weight and cancer risk; and (vii) psychological stressors and cancer risk. Three aspects of the body's NE system are consistent with it playing an etiological role in various types of cancer: (i) NE circulates in the blood and can thereby access organ systems throughout the body, in addition to direct peripheral release by the sympathetic nervous system and being released within the brain; (ii) many of the body's organs possess NE receptors on the outer surface of at least some of their cells; (iii) by binding to its extracellular receptors, NE affects intracellular second messenger systems that could influence carcinogenesis. Most importantly, use of existing pharmaceutical drugs that either lower the level of NE (such as clonidine) or block NE receptors may lower the probability of an individual developing cancer, and this hypothesis could be tested immediately by an epidemiologist through examination of existing medical records. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19004004     DOI: 10.1002/ijc.24063

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

2.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

3.  The catecholamine biosynthetic enzyme dopamine β-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter.

Authors:  Maja Mustapic; Adam X Maihofer; Manjula Mahata; Yuqing Chen; Dewleen G Baker; Daniel T O'Connor; Caroline M Nievergelt
Journal:  Hum Mol Genet       Date:  2014-06-30       Impact factor: 6.150

4.  Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma.

Authors:  Jing-Jing He; Wen-Hua Zhang; Shi-Ling Liu; Yi-Fang Chen; Chen-Xi Liao; Qian-Qing Shen; Ping Hu
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

5.  Norepinephrine antagonists and cancer risk.

Authors:  Gary D Friedman; Natalia Udaltsova; Laurel A Habel
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 6.  Implications of corticotropin releasing factor in targeted anticancer therapy.

Authors:  Byung-Jin Kim; Harlan P Jones
Journal:  J Pharm Pract       Date:  2010-02-17

7.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

8.  VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors.

Authors:  Bruna Maria Rodrigues Vilardi; Diego Mauricio Bravo-Calderón; Daniel Galera Bernabé; Sandra Helena Penha Oliveira; Denise Tostes Oliveira
Journal:  Tumour Biol       Date:  2012-10-12

9.  Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer.

Authors:  Paul J Fitzgerald
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

10.  Spinal anesthesia does not impact prostate cancer recurrence in a cohort of men undergoing radical prostatectomy: an observational study.

Authors:  Kenneth S Tseng; Sachin Kulkarni; Elizabeth B Humphreys; H Ballentine Carter; Jacek L Mostwin; Alan W Partin; Misop Han; Christopher L Wu
Journal:  Reg Anesth Pain Med       Date:  2014 Jul-Aug       Impact factor: 6.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.